Interv Akut Kardiol. 2020;19(4):215-221 | DOI: 10.36290/kar.2020.033

What to expect from direct oral anticoagulant monitoring

Miroslav Penka, Jan Novotný

Oddělení klinické hematologie, FN Brno

In our quest for an ideal antithrombotic drug with therapeutic efficacy and a good safety profile with a possibility of parenteral administration, rapid onset of action, no need for routine laboratory checks, few or no drug-drug and drug-food interactions, and economic availability, we have arrived at direct oral anticoagulants (DOACs) which get us a step closer to meet these requirements. Although not necessary, laboratory monitoring of the effect of DOACs can be appropriate in the setting of bleeding, overdose, treatment failure, before acute interventional procedures and operations, in renal insufficiency, in drug interactions, in the case of extreme weight (below 50 kg and above 100 kg) and, finally, in assessing patient compliance.

Keywords: direct thrombin and factor Xa inhibitors, direct oral anticoagulants, indications and monitoring.

Received: July 1, 2020; Revised: July 1, 2020; Accepted: July 1, 2020; Prepublished online: July 1, 2020; Published: December 3, 2020  Show citation